RNSs16 Nov 2018 10:50
Very pleased with today’s fundraising announcement of £6m at a placing price of 23p, which is at only a very minimal discount to even the latest buy of 23.84p. If they successfully complete this, and it looks like they will, this is brilliant in the current market, in my humble opinion.
Generally, progress on HCV sales is a bit slower than I had hoped and the timeline on the relaunch of the TB test is disappointing. However, great news that the US DoD programme has moved into a commercial phase and that we have received the first commercial deployment order for $0.9m of instruments and assays. It sounds like we might get further orders and better visibility on future orders as well.
A significant unexpected bonus for us shareholders, I think, is the newly announced qualification under EIS. I am no expert on this but as I read it, this means that we will be able to claim a tax rebate of 30% of the cost of our shares, subject to conditions, as well as offset any future losses (after allowing for income tax relief already claimed) against capital gains or taxable income.
That surely makes GDR more attractive for long term investors and, unless I am missing something, is equivalent to a 30% boost in SP (or, looked at another way, a recovery of at least 30% of losses already incurred) albeit subject to a successful claim for relief. If that is right, happy days!